<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04817267</url>
  </required_header>
  <id_info>
    <org_study_id>IRB00282938</org_study_id>
    <nct_id>NCT04817267</nct_id>
  </id_info>
  <brief_title>Pilot Study of reSET-O to Treatment-as-usual in Acute Care Settings</brief_title>
  <official_title>Pilot Study of reSET-O to Treatment-as-usual in Acute Care Settings</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Johns Hopkins University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Pear Therapeutics, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Johns Hopkins University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This randomized controlled pilot study will evaluate feasibility, acceptability, and&#xD;
      potential efficacy of an app, reSET-O, for patients being started on buprenorphine in acute&#xD;
      care settings.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This randomized controlled pilot study will enroll 60 participants, who will be randomly&#xD;
      assigned to a treatment as usual (TAU) group or a reSET-O+TAU group after being started on&#xD;
      buprenorphine in acute care settings (e.g., emergency department) and referred to community&#xD;
      treatment. Study enrollment will last for 3 months after discharge from the acute care&#xD;
      setting. Participants in the reSET-O+TAU group will be provided with the reSET-O app and will&#xD;
      be encouraged to engage with the app for the 3 months following discharge from the acute care&#xD;
      unit. The app works as an extension of cognitive behavioral therapy, providing&#xD;
      psychoeducation related to opioid use disorder. All participants will be assessed at study&#xD;
      intake and every month during the 3-month intervention.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">March 1, 2022</start_date>
  <completion_date type="Anticipated">March 1, 2024</completion_date>
  <primary_completion_date type="Anticipated">March 1, 2023</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of approached patients who are eligible for and interested in participation</measure>
    <time_frame>3 months</time_frame>
    <description>Percentage of approached patients who are eligible for and interested in participation will be used to assess feasibility.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Acceptability as assessed by the Treatment Acceptability Questionnaire</measure>
    <time_frame>3 months</time_frame>
    <description>Participant responses to the Treatment Acceptability Questionnaire.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Acceptability as assessed by the System Usability Scale</measure>
    <time_frame>3 months</time_frame>
    <description>Participant responses to the System Usability Scale.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Attendance at follow-up appointment for on-going buprenorphine treatment within 30 days of discharge</measure>
    <time_frame>30 days</time_frame>
    <description>Attendance at follow-up appointment for on-going buprenorphine treatment within 30 days of discharge will be used to assess Treatment Engagement.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of drug-negative urine samples during the 3-month intervention</measure>
    <time_frame>3 months</time_frame>
    <description>Percentage of drug-negative urine samples during the 3-month intervention will be used to assess Illicit opioid/other drug use.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Opioid-use Disorder</condition>
  <arm_group>
    <arm_group_label>reSET-O + Treatment-As-Usual (TAU)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants randomly assigned to this group will receive the TAU plus the reSET-O app.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Treatment-As-Usual (TAU)</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Participants randomly assigned to this group will receive the TAU only (no use of the reSET-O app).</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>reSET-O app</intervention_name>
    <description>The reSET-O app, a prescription digital therapeutic, provides cognitive behavioral therapy for opioid use disorder. The app provides psychoeducation related to opioid use, coping skills, and skills to avoid relapse.</description>
    <arm_group_label>reSET-O + Treatment-As-Usual (TAU)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  18-65 years old&#xD;
&#xD;
          -  Opioid use disorder&#xD;
&#xD;
          -  Eligible for buprenorphine treatment&#xD;
&#xD;
          -  Has reSET-O compatible mobile device&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Pregnancy&#xD;
&#xD;
          -  Significant psychiatric comorbidity&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>August Holtyn</last_name>
    <role>Principal Investigator</role>
    <affiliation>Johns Hopkins University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>August Holtyn</last_name>
    <phone>4105509691</phone>
    <email>aholtyn1@jhmi.edu</email>
  </overall_contact>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>March 23, 2021</study_first_submitted>
  <study_first_submitted_qc>March 23, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">March 26, 2021</study_first_posted>
  <last_update_submitted>November 9, 2021</last_update_submitted>
  <last_update_submitted_qc>November 9, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 11, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Opioid-Related Disorders</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

